SUMMARY Three hundred and seventy nine patients who had undergone mitral valve replacement using unstented antibiotic sterilised aortic homografts were followed up for 52 to 138 months (mean 102 months). Patients requiring additional aortic valve replacement were excluded. The commonest cause was rheumatic heart disease (321 patients). There were 37 early deaths (9.8%) and 97 late deaths (28%). The actuarial survival of operative survivors was 83% at three years, 75% at five years, and 55% at nine years. Technical valve failure occurred in six patients (1*6%), infective endocarditis in 19 (5%), and degeneration of the valve in 43 (12-5%). The cumulative probability of freedom from endocarditis was 96% at three years, 94% at five years, and 91% at nine years, while that of freedom from valve degeneration was 97% at five years and 48% at 10 years. There were no early embolic episodes, but late embolism occurred in five patients (1.5%).
Although mitral valve replacement is an established procedure, the search for an ideal valve substitute continues because of the relatively high incidence of valve related complications. A technique for replacing the mitral valve by unstented aortic homografts was developed in 1968.' In this report we have analysed their long term performance.
Patients and methods
Between August 1969 and June 1977, 379 patients underwent replacement of the mitral valve using inverted unstented antibiotic sterilised aortic homografts. Patients requiring additional aortic valve replacement were excluded from this series. There were 137 men ranging in age between 24 and 72 years (mean 51 years) and 242 women ranging in age between 18 and 71 years (mean 50 years). The age and sex distribution is shown in Fig. 1 . All patients were in NYHA classification class III or IV. The commonest cause of valve disease was rheumatic heart disease in 321 patients (85%), followed by floppy valve syndrome in 42 patients (11%), and ischaemic heart disease in 16 patients (4%).
Three hundred and thirty one patients underwent isolated mitral valve replacement and 48 patients (13%) had additional procedures. These included decortication of the left atrium in 17 patients, tricuspid valve replacement in 12, tricuspid annuloplasty in Accepted for publication 19 April 1983 six, coronary bypass grafting in 10, and closure of an atrial septal defect in three patients (Table 1) . TECHNIQUE The method of preparation and the technique of insertion of the aortic homograft have been described previously. 2 (Table 2) There were 97 (28%) late deaths during a follow-up period of 52 to 138 months (mean 102 months). The cause of death was cardiac in 62 patients (18%), miliary tuberculosis in four (1%), and non-cardiac in 20 (6%). In and 61 months after operation. All these patients were subsequently anticoagulated with warfarin. Actuarial analysis showed a predicted thromboembolism free rate of 98% at five years and 97-5% at nine years ( Fig. 5) .
VALVE FAILURE Technical Technical failure occurred in six patients (1.6%). In four patients it occurred in the early postoperative period (within four months). These patients presented with acute pulmonary oedema and died. At Staphylococcus aureus in two). In the remaining three patients no organisms were isolated ( Table 3) . Nine of the 19 patients underwent reoperation for haemodynamic sequelae of endocarditis when the homograft was replaced using a prosthetic valve. Four patients are alive and five died, four early and one late as a result of congestive cardiac failure. The remaining 10 patients who did not undergo reoperation all died.
DEGENERATION
Of the operative survivors, there were 43 (12-5%) degenerative valve failures. The probability of freedom from degeneration was 97% at five years, 82% at eight years, and 48% at 10 years (Fig. 7) . There was an increase in the rate of degeneration after the seventh year.
The Of the patients with their original homograft, 66% are in NYHA classification class I, 26% are in class II, and 7% are in class III (Table 4 ). In the group of patients whose homograft has been replaced, 48i5% are in class I, 48i5% in class II, and 3% in class III.
Discussion
In an attempt to find the ideal substitute for the diseased mitral valve, the technique of using inverted antibiotic sterilised aortic homografts was Follow-up (years) 9 10 Fig. 9 Probability offreedom from degeneration in aortic homograft replacement of mitral valve compared with porcine xenograft replacement of mitral valve. 14 Qureshi, Halim, Campalani, Coe, Towers, Yacoub replacement with other tissue valves has given satisfactory results for up to seven years.9 [14] [15] [16] There is, however, still uncertainty about their behaviour for longer periods than that. In a recent report of a large series of mitral valve replacement using porcine xenografts,'5 the probability of freedom from degeneration was 63% at eight yeqrs compared with 82% in our series and there was an increase in degeneration after the sixth and seventh years (Fig. 9) .
The aortic homograft is capable of satisfactory function for 10 or more years in some patients. Routine investigation of some of our patients at 10 years has shown normal function of the valves. The factors that govern the rate of homograft degeneration are unknown but may include: (1) the age of the donor; (2) methods of preparation and preservation; (3) methods of insertion; (4) immunological reaction resulting in a process of ongoing slow rejection.
Although in our series, no children were included, our experience with homograft replacement of the aortic valve'17 has shown that the rate of degeneration was slower than that observed in adults possibly because of the lower arterial pressure in younger patients. From the data available, it appears that the use of unstented homografts in this age group could be the best currently available valve substitute, particularly in view of the difficulties of long term anticoagulation and the fact that porcine xenografts have an alarmingly high rate of degeneration in children.18 19 The incidence of endocarditis (5%) in this series has been relatively high compared with that reported for mechanical prosthesis which varied from 0 to 4% in patients followed for shorter periods.2022 The risk of endocarditis continued to increase during the period of follow-up. Early infection (within the first six months) accounted for about 400/o of all cases of endocarditis. In these patients, the infection could have been the result of inadequate sterilisation of the homograft or introduced during the perioperative period. Routine Homograft endocarditis carried an operative mortality of 44% for reoperation with an overall mortality of 79%. The best results were obtained in the patients in whom the infection was successfully treated by antibiotics, followed by elective replacement of the malfunctioning homograft.
Reoperation as a result of valve failure resulting from degeneration carried a slightly increased operative mortality (11%). This is partly because of the late referral of the patients. Over the past four years, because of earlier intervention, the operative mortality for reoperation is 6-2% (one death out of 16 patients). Familiarity with the technique of removing the homograft may have contributed to the improved operative mortality.
In adults, this valve has produced results similar to those with porcine xenografts, with perhaps a marginally slower rate of degeneration. One of the disadvantages of unstented homografts in the mitral position, however, is that their replacement constitutes a more involved procedure and requires familiarity with the exact method of insertion. In children the use of unstented homografts offers the advantage of the slowest rate of degeneration of tissue valves currently available. Though this form of valve replacement is now seldom used in adults in our institution, continued analysis of its long term performance and the factors that could influence it are being made in an attempt to define its role in the future. 
